Platinum-Resistant Malignant Female Reproductive System Neoplasm

Platinum-Resistant Malignant Female Reproductive System Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

112 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 58
Recruiting: 30
Ph III recruiting: 3
Growth YoY: —
Industry share: 47%
Top sponsor: National Cancer Institute (NCI)
Termination share: 53.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (25)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04840589	Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors	suspended	Phase 1	66	National Cancer Institute (NCI)NIH	1	Aug 17, 2026	clinicaltrials

Data updated 22 days agoSource updated Aug 17, 2026source: clinicaltrials